Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease

Autor: Daniel Birnbaum, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Renaud Sabatier, François Bertucci, Roxane Mari
Přispěvatelé: Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., mamessier, emilie, Sabatier, Renaud
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Diagnostic methods
[SDV.CAN]Life Sciences [q-bio]/Cancer
Review
Disease
circulating tumor cells
[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics
lcsh:RC254-282
03 medical and health sciences
liquid biopsies
0302 clinical medicine
Circulating tumor cell
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Ovarian carcinoma
medicine
Subclinical disease
circulating exosomes
ComputingMilieux_MISCELLANEOUS
circulating tumor DNA
business.industry
Advanced stage
[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Treatment efficacy
3. Good health
circulating miRNA
030104 developmental biology
ovarian cancer
030220 oncology & carcinogenesis
[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy
Ovarian cancer
business
Zdroj: Cancers
Cancers, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩
Cancers, MDPI, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩
Cancers, Vol 11, Iss 6, p 774 (2019)
ISSN: 2072-6694
DOI: 10.3390/cancers11060774⟩
Popis: Ovarian cancers (OvC) are frequent, with more than 22,000 new cases each year for 14,000 deaths in the United States. Except for patients with BRCA1 or BRCA2 mutations, diagnostic methods, prognostic tools, and therapeutic strategies have not much improved in the last two decades. High throughput tumor molecular analyses have identified important alterations involved in ovarian carcinoma growth and spreading. However, these data have not modified the clinical management of most of patients. Moreover, tumor sample collection requires invasive procedures not adapted to objectives, such as the screening, prediction, or assessment of treatment efficacy, monitoring of residual disease, and early diagnosis of relapse. In recent years, circulating tumor biomarkers (also known as “liquid biopsies”) such as circulating tumor cells, circulating nucleotides (DNA or miRNA), or extracellular vesicles, have been massively explored through various indications, platforms, and goals, but their use has not yet been validated in routine practice. This review describes the methods of analysis and results related to liquid biopsies for ovarian epithelial cancer. The different settings that a patient can go through during her journey with OvC are explored: screening and early diagnosis, prognosis, prediction of response to systemic therapies for advanced stages, and monitoring of residual subclinical disease.
Databáze: OpenAIRE
Externí odkaz: